These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30295107)

  • 21. Access to treatment for opioid use disorders: Medical student preparation.
    McCance-Katz EF; George P; Scott NA; Dollase R; Tunkel AR; McDonald J
    Am J Addict; 2017 Jun; 26(4):316-318. PubMed ID: 28394437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of buprenorphine treatment for opioid dependence.
    Murphy SM; Fishman PA; McPherson S; Dyck DG; Roll JR
    J Subst Abuse Treat; 2014 Mar; 46(3):315-9. PubMed ID: 24209382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanded buprenorphine prescribing privileges: Sandbagging in the midst of the flood?
    Brown JD; Nolte JL
    Res Social Adm Pharm; 2018 Jun; 14(6):617-618. PubMed ID: 29525482
    [No Abstract]   [Full Text] [Related]  

  • 26. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy.
    O'Connor AB; Collett A; Alto WA; O'Brien LM
    J Midwifery Womens Health; 2013; 58(4):383-8. PubMed ID: 23931660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
    Meshberg-Cohen S; Black AC; DeViva JC; Petrakis IL; Rosen MI
    Addict Behav; 2019 Feb; 89():29-34. PubMed ID: 30243036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
    Doernberg M; Krawczyk N; Agus D; Fingerhood M
    Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing Access to Buprenorphine in Safety-Net Primary Care Clinics: The New York City Buprenorphine Nurse Care Manager Initiative.
    Kaplan-Dobbs M; Kattan JA; Tuazon E; Jimenez C; Saleh S; Kunins HV
    Am J Public Health; 2021 Feb; 111(2):215-218. PubMed ID: 33351661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy.
    Mittal L; Suzuki J
    Subst Abus; 2017; 38(3):261-264. PubMed ID: 26672650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buprenorphine use and setting type among reproductive-aged women self-reporting nonmedical prescription opioid use.
    DeSisto CL; Terplan M; Kacha-Ochana A; Green JL; Mueller T; Cox S; Ko JY
    J Subst Use Addict Treat; 2023 Dec; 155():209083. PubMed ID: 37245854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The payer's role in addressing the opioid epidemic: It's more than money.
    Molfenter T; McCarty D; Jacobson N; Kim JS; Starr S; Zehner M
    J Subst Abuse Treat; 2019 Jun; 101():72-78. PubMed ID: 31174716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary.
    McElrath K
    Subst Use Misuse; 2018 Jan; 53(2):334-343. PubMed ID: 28862903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention.
    Williams AR; Mauro CM; Feng T; Wilson A; Cruz A; Olfson M; Crystal S; Samples H; Chiodo L
    Am J Psychiatry; 2023 Jun; 180(6):454-457. PubMed ID: 36285405
    [No Abstract]   [Full Text] [Related]  

  • 38. Randomized pilot trial of Web-based cognitive-behavioral therapy adapted for use in office-based buprenorphine maintenance.
    Shi JM; Henry SP; Dwy SL; Orazietti SA; Carroll KM
    Subst Abus; 2019; 40(2):132-135. PubMed ID: 30714880
    [No Abstract]   [Full Text] [Related]  

  • 39. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.
    Shcherbakova N; Tereso G; Spain J; Roose RJ
    Ann Pharmacother; 2018 May; 52(5):405-414. PubMed ID: 29302989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.